Mars Inc. and NVA Own 75% of Emergency Vet Clinics, Driving Up Prices

Corporate consolidation in veterinary medicine has reached a point where two parent companies — Mars Inc. (through VCA, Banfield, and BluePearl) and National Veterinary Associates (NVA) — control an estimated 75% of emergency and specialty veterinary clinics in the United States. When a pet owner rushes their dog to the ER at 2 AM, they often have no choice but to walk into a corporate-owned facility, even if they don't realize it. The clinic may still carry its old independent name on the sign, but the pricing, staffing, and protocols are set by a private-equity-backed holding company thousands of miles away. This matters because emergency vet visits have become shockingly expensive, and there is no competitive pressure to bring prices down. A dog that swallows a sock might face a $4,000-$6,000 bill for imaging, sedation, and endoscopic retrieval — a procedure that cost $1,200 at the same clinic five years ago before acquisition. Pet owners who cannot pay are told to apply for CareCredit, a high-interest medical credit card, or surrender the animal. There is no price transparency, no ability to comparison-shop mid-emergency, and no regulatory body capping markups on veterinary drugs or services the way there is (however imperfectly) in human medicine. The downstream consequence is that millions of pets go untreated. The American Veterinary Medical Association estimates that 29% of pet-owning households have skipped or delayed veterinary care due to cost, up from 22% a decade ago. Animals suffer from treatable conditions — infections, fractures, diabetic crises — because their owners cannot afford a corporatized price point. Some owners resort to euthanasia purely because treatment costs exceed what they can pay, a phenomenon vets call "economic euthanasia." This persists because veterinary medicine is essentially unregulated from an antitrust perspective. The FTC has not blocked a single veterinary clinic acquisition. Mars Inc. alone has spent over $9 billion acquiring veterinary businesses since 2007, and because each acquisition is individually small (a single clinic), none triggers Hart-Scott-Rodino reporting thresholds. The result is monopoly-level market concentration assembled one small deal at a time, completely under the regulatory radar.